Get the Stockscreener App
6.04
2.74%
-0.17
After Hours:
6.04
Valneva Se Adr stock is traded at $6.04, with a volume of 18,299.
It is down -2.74% in the last 24 hours and down -17.49% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
See More
Previous Close:
$6.21
Open:
$6.15
24h Volume:
18,299
Relative Volume:
1.60
Market Cap:
$489.70M
Revenue:
$163.13M
Net Income/Loss:
$-34.75M
P/E Ratio:
44.94
EPS:
0.1344
Net Cash Flow:
$-231.66M
1W Performance:
+2.20%
1M Performance:
-17.49%
6M Performance:
-23.74%
1Y Performance:
-47.84%
1-Day Range:
$5.91
$6.15
1-Week Range:
$5.895
$6.5451
52-Week Range:
$5.70
$14.49
Valneva Se Adr Stock (VALN) Company Profile
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy - Investing.com
In-Depth Examination Of 6 Analyst Recommendations For Valneva - Benzinga
Valneva Announces the Success of its Private Placement Raising approximately €60 Million - GlobeNewswire Inc.
Valneva shares hold strong with buy rating on Lyme vaccine data - Investing.com
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know - MSN
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock - Zacks Investment Research
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know - Yahoo Finance
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3% - Yahoo Finance
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
What Analysts Are Saying About Valneva Stock - Benzinga
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine - Zacks Investment Research
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine - Yahoo Finance
Wall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High? - Yahoo New Zealand News
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval - Yahoo Finance
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Yahoo Sport Australia
What Analysts Are Saying About Valneva Stock - Benzinga
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar? - Yahoo New Zealand News
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why - Yahoo Lifestyle UK
Cracking The Code: Understanding Analyst Reviews For Valneva - Benzinga
Earnings call: Valneva reports robust growth and strategic R&D focus By Investing.com - Investing.com South Africa
France stocks mixed at close of trade; CAC 40 up 0.34% By Investing.com - Investing.com
France stocks mixed at close of trade; CAC 40 up 0.91% - Investing.com
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Nasdaq
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why - Yahoo Finance
What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock - Yahoo Finance
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab - Yahoo Lifestyle Singapore
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe - Zacks Investment Research
5 Top Health Care Stocks To Watch In The Stock Market Today - Stock Market
Valneva SEADR Shares Close in on 52-Week HighMarket Mover - Nasdaq
Valneva Stock Is Jumping on European Vaccine Supply Deal - Barron's
Valneva Stock Surges After EU Vaccine Deal - Investing.com
Valneva Shares Off 12% On Share Offering News By Investing.com - Investing.com UK
EU set to sign off new Pfizer vaccine contract as soon as Friday - Luxembourg Times
Valneva Races Ahead in Stock Market Even as Vaccine Lags Behind - Bloomberg
Shareholder Structure - Valneva
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):